Related Experiment Video

Updated: Jun 8, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

PKD2 mediates multi-drug resistance in breast cancer cells through modulation of P-glycoprotein expression

Jiao Chen1, Libing Lu, Yun Feng

  • 1State Key Laboratory of Oral Diseases, West China College of Stomatology, Sichuan University, PR China. cj0123@163.com

Cancer Letters
|October 12, 2010
PubMed

Insights

Protein kinase D isoform 2 (PKD2) regulates multi-drug resistance (MDR) in breast cancer by controlling P-glycoprotein (P-gp) expression. Inhibiting PKD2 may enhance chemotherapy effectiveness against drug-resistant cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Multi-drug resistance (MDR) is a significant challenge in cancer chemotherapy.
  • Increased expression of drug efflux pumps like P-glycoprotein (P-gp) is a key mechanism of MDR.
  • Protein kinase D isoform 2 (PKD2) is investigated for its role in MDR.

Purpose of the Study:

  • To identify regulators of MDR and P-gp expression in paclitaxel-resistant breast cancer cells.
  • To investigate the role of PKD2 in paclitaxel-induced MDR and P-gp expression.
  • To evaluate PKD2 modulation as a potential therapeutic strategy.

Main Methods:

  • Utilized MDA-MB-231 breast cancer cell lines, known for high drug resistance.
  • Assessed PKD2 expression and phosphorylation status.
  • Investigated the effect of paclitaxel treatment on PKD2 and P-gp.
  • Performed shRNA-mediated knockdown of PKD2 to assess its impact on drug resistance and P-gp expression.

Main Results:

  • PKD2 showed high phosphorylated activation in MDA-MB-231 cells, which exhibit high drug resistance.
  • Paclitaxel treatment induced time-dependent phosphorylation of PKD2 and increased P-gp expression.
  • Knockdown of PKD2 significantly reduced paclitaxel resistance (decreased IC50 and RI).
  • PKD2 knockdown also reduced paclitaxel-induced P-gp expression.

Conclusions:

  • PKD2 is essential for paclitaxel-induced multi-drug resistance and P-gp expression in breast cancer cells.
  • Targeting PKD2 activity presents a promising therapeutic approach to overcome chemotherapy resistance.
  • Modulating PKD2 could improve the clinical efficacy of existing chemotherapeutic agents.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect01:26

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...